Getting International Exposure in ETFs Isn't Always an Easy Choice. Is SPGM or IEFA the Better Buy for 2026?

The real signal here is factor packaging, not ETF selection. SPGM is functionally a U.S. large-cap tech proxy with a global wrapper, so it will look “better” only as long as U.S. megacap dominance persists; that makes it a poor diversification tool for portfolios already heavy in SPY/QQQ. IEFA is the cleaner hedge against domestic concentration, with a more defensive factor mix and better sensitivity to a weaker dollar, slower U.S. growth, or a rotation into non-U.S. cyclicals and financials.

Second-order, the biggest beneficiaries of a true ex-U.S. allocation are the names that sit at the core of IEFA’s factor mix: ASML, HSBC, and broader European/Japanese financials/industrials. Conversely, SPGM mainly adds incremental ownership to AAPL/MSFT/NVDA, so the overlap risk is high and the marginal diversification benefit is low. The fee difference is immaterial; the decision should be made on portfolio construction and regime view, not cost.

Contrarian view: the market is still rewarding the same U.S. factor crowd that has driven SPGM’s outperformance, but that can reverse quickly if AI capex expectations decelerate, mega-cap multiples compress, or ex-U.S. earnings revisions turn up. Over the next 1-3 months, a broad U.S. tech drawdown would likely make SPGM look like a disguised beta trade rather than a world fund. Over 6-18 months, if the dollar softens and global breadth improves, IEFA should outperform on a lower-volatility basis.